Background
Chronic hepatitis C is an important public health problem, with an estimated 71 million people living with the hepatitis C virus (HCV) across the globe in 2015 [
1]. If left untreated, hepatitis C can progress to serious liver disease; the estimated probability of cirrhosis at 20 years after HCV infection is 16% [
2].
The recent introduction of simple, highly effective and well-tolerated direct-acting antiviral (DAA) treatment regimens for HCV provides an opportunity to reduce prevalence and ultimately eliminate HCV infection as a public health threat [
3]. For example, significant progress towards HCV elimination has been made in Iceland, with 81% (603/741) of people identified as HCV-positive cured through a 3-year national elimination programme [
4]. To achieve HCV elimination, treatment of populations at high risk of infection such as people who inject drugs (PWID), should be prioritised [
5]. In Europe, HCV prevalence among people with recent injection drug use is between 39.9 and 48.6% whereas HCV prevalence in the general population is approximately 1.5% [
1,
6]. In fact, injection drug use is the main driver of HCV infection in Europe, with approximately 80% of new cases attributable to this high-risk behaviour [
7]. Although DAA therapy can cure the majority of people living with HCV, there are still some physical and psychological barriers that prevent people, including PWID, from accessing HCV care and treatment [
8,
9]. The psychological impact of living with hepatitis C is well-documented with many people experiencing depression and anxiety [
10,
11]. These symptoms, which are very common among PWID, may affect people’s willingness to initiate HCV treatment [
12,
13].
There is a gap in knowledge on the factors that encourage PWID to start DAA treatment and on the impact treatment has on drug-user health, practices and wellbeing. Therefore, the aim of this investigation was to survey injection drug users who have received DAA treatment in order to gain insights on the non-clinical impact that HCV treatment has had on their life, and on wider society. Additionally, the study aimed to ascertain the main reasons these participants were motivated to access and complete HCV treatment, as well as survey the participants’ opinions on the factors that may encourage more PWID to engage in HCV care.
Methods
Study population
Participants included in this study were aged between 25 and 67 years, were either injecting opioids or stimulants regularly (at least once a week), injecting occasionally (less than once a week) or had previously injected opioids or stimulants. The participants had also received a confirmed diagnosis of hepatitis C (self-reported) and completed DAA treatment. Participants were incentivised to take part in the study in the form of vouchers. Each participant was offered physical or digital vouchers (supermarket or Amazon) worth 50 euros (£50 in the UK).
Recruitment
The aim was to recruit eight injection drug users per country in the UK (Brighton and Blackpool), France (Montpellier and Marseille), Germany (Essen and Cologne), Italy (Rome) and Spain (Bilbao), and six injection drug users per country in Portugal (Lisbon and Porto) and Switzerland (Lugano). Recruitment channels in these countries included patient associations/organisations, referrals from healthcare professionals (HCPs), recruiter panels (local databases of patients and HCPs from a variety of specialties), patient referrals and online campaigns. Invitations to participate in the survey were sent via these channels in September 2018. A team of local fieldwork partners/recruiters with experience in healthcare market research conducted recruitment in each of the countries. Physicians (from the recruiter panels) and patient associations/organisations were contacted by email or telephone to invite them to assist with patient referrals. In this communication, they were provided with a letter detailing information about the study, invited to help refer suitable patients and given details of the referral incentive. The incentive consisted of donations ranging from 100 to 1000 euros or £100–£1000 in the UK (depending on how many participants were referred) to charities and addiction centres for their support in referring participants. Physical or digital vouchers (supermarket or Amazon) worth 50 euros (£50 in the UK) were offered to participants who referred other participants to the survey. In Portugal, there were no incentives given for referrals due to country regulations. No healthcare professionals were paid any referral incentives. Physicians were invited to tell patients about the study and provide them with the recruiter’s contact details. Patients were free to contact the recruiter if they were interested in participating. The recruiters also advertised the study and provided information about how to take part via various channels including the recruiter panel website, social media and patient association forums, newsletters and websites.
Survey
The survey questionnaire was developed by Incite, an independent international market research consultancy (Supplementary File
1). The authors, who have a wide knowledge of hepatology and addiction, contributed to the development of the questionnaire and decisions on which outcomes to measure. They reviewed the final version to ensure alignment with the research objectives and that the questions were appropriate for participants. The survey comprised of 25 questions relating to participants’ sociodemographic characteristics, injecting behaviours and HCV treatment. The survey also included seven questions on the perceived impact of HCV treatment on different aspects of the participants’ lives. The survey was hosted online on the Confirmit platform.
Once participants had agreed to participate, the online survey was conducted in-person (as a face-to-face interview) in the native language at a convenient location (e.g. a café, HCV nurse’s office, rehabilitation centre, drug addiction clinic or patient’s home). The interviews were carried out by moderators (non-HCPs) with experience working in healthcare market research, including patient research. All moderators had received training on how to ask questions on topics of a sensitive nature. At the beginning of every interview, participants were reassured on the anonymity of their responses to encourage open and honest feedback. All responses provided by the participant were inputted onto a tablet or laptop by the moderator. Data were collected on the Confirmit platform. Incite researchers and analysts collated and analysed the data using Q Research Software.
Data collection
The surveys were carried out from 13 September 2018 to 11 April 2019 and took 30 min to complete on average.
Discussion
This survey analysis shows that there are additional benefits to HCV treatment in PWID other than cure; many participants experienced a positive impact on other outcomes, mainly in their subjective psychological/mental health. These results align with previous studies which demonstrate that HCV treatment has a transformative effect on patients’ quality of life and mental wellbeing [
14‐
17].
Despite these benefits, global HCV treatment uptake among PWID is low [
18,
19]. There are many system-level and provider-level reasons for this low treatment uptake but at an individual level, lack of awareness of HCV diagnosis, previous negative experiences with healthcare systems, stigma and physical/psychological co-morbidities have been identified as common barriers for PWID [
20‐
22]. Another key barrier is lack of knowledge or misinformation about HCV and how it is treated [
20]. Until 2013, the only treatments that were available for HCV were interferon (IFN)-based and required weekly injections for up to 1 year [
23]. These IFN-based regimens were associated with many side effects and low efficacy rates, particularly among PWID [
24,
25]. Negative experiences of these poorly tolerated regimens have been shared among drug user communities which has resulted in many people being fearful of treatment side effects [
26,
27].
With the advent of well-tolerated and orally administered DAA drugs, HCV treatment has become simpler and the majority of infected individuals, including PWID, can be treated and cured [
28]. There is now consensus among the medical community that all patients should be able to access care and that treating PWID in particular is a priority to reduce HCV transmission [
5,
29]. Pangenotypic regimens that are currently available require minimal pre-, during and post-treatment monitoring and can be used effectively to treat large numbers of previously underserved populations, thus maximising efforts towards HCV elimination [
30].
There is still a need to understand what motivates PWID to engage in care. Qualitative research has illustrated that eliminating the virus is not the only factor that motivates PWID to start therapy [
31]. The results of our survey suggest that awareness of the availability of effective and well-tolerated treatments and the potentially severe consequences of untreated HCV are key motivators. This highlights the importance of developing programmes and initiatives that include patient education to ensure that more PWID are treated for HCV [
32]. In the Netherlands, education and awareness campaigns targeted at PWID have already been proven to be successful at engaging more individuals into care, with 257 additional PWID diagnosed with chronic HCV when these interventions were used compared to the control group [
33]. An interesting topic for further research would be to survey PWID who decline HCV treatment to understand which factors influence their decision making.
Even in the era of simple DAA treatments that are effective in many patient populations, management of HCV among PWID is often perceived as challenging because this population is usually stigmatised by society and can find healthcare services difficult to access [
21,
22,
34]. However, findings from this survey suggest that the majority of PWID reported a positive impact on their ability to engage in wider society and explore new interests/hobbies after HCV treatment. Previous studies have also shown similar positive outcomes beyond HCV cure that are valued highly among PWID [
16,
31].
In this analysis, there was wide variation in injecting patterns between participants, with different numbers of participants injecting drugs before and after HCV treatment. This highlights the complexity of this patient population and should be considered when interpreting the results. For example, for some outcomes such as overall outlook for the future, ability to plan for the future and empowerment, there was a large difference in the number of participants who reported a positive impact with HCV treatment between those who used drugs at the time of the survey and those who did not. It is not clear why this is the case however it suggests that injection drug use could also have an impact on these outcomes. Previous research has demonstrated that stopping drug use can improve an individual’s mental and physical health, and therefore their quality of life [
35,
36].
The results of this research should be interpreted in light of several limitations. First, given the nature of the data, it was not appropriate to conduct statistical analyses so we cannot draw reliable statistical comparisons between different categories of patients. Therefore, our results should be viewed as indicators for future studies. The cross-sectional nature of the survey must also be taken into account when analysing these results as for many participants, there was variation in the time between completing treatment and completing the survey. In addition, this study only presents data on the aspects of life mentioned in the survey and so there may be more benefits of treatment that are not described. Finally, we report results from a survey of PWID who had volunteered and were therefore motivated to participate. We cannot guarantee that the findings are representative of all people who use drugs.
It is also important to highlight the specific strengths of this research. For example, this is one of the first analyses that focus on the self-perceived impact of HCV treatment on mental health and physical wellbeing in people who inject drugs. Many of the outcomes that we report on have not been measured in clinical trials and so these findings add breadth to the literature on patient-level benefits of HCV treatment. In addition, information from this survey allows us to gain insights on a high-risk and highly stigmatised population that is usually excluded from healthcare programmes and large randomised controlled clinical trials. One of the benefits of this study was that recruitment of participants was driven by patients with the majority recruited through patient associations/organisations. A possible reason for this is that PWID visit community-based organisations more regularly than other healthcare settings [
37]. In general, this survey shows that having a variety of different recruitment channels is valuable when recruiting PWID.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.